Holen Sie sich die Stockscreener-App
32.47
1.67%
-0.55
Vorhandelsmarkt:
32.42
-0.05
-0.15%
Schlusskurs vom Vortag:
$33.02
Offen:
$33.06
24-Stunden-Volumen:
308.52K
Relative Volume:
0.30
Marktkapitalisierung:
$1.93B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.95M
KGV:
-16.14
EPS:
-2.0123
Netto-Cashflow:
$-95.28M
1W Leistung:
-12.34%
1M Leistung:
-13.07%
6M Leistung:
+53.74%
1J Leistung:
+238.58%
1-Tages-Spanne:
$32.16
$33.45
1-Wochen-Bereich:
$32.16
$37.22
52-Wochen-Spanne:
$8.75
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
32.47 | 1.96B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Guggenheim | Buy |
| 2026-04-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
TYRA Pulls Back: Market Rotation Hits Communication - Newser
Tyra Biosciences, Inc. Stock 12‑Month Price Target Raised to $51.78, Implies 59% Upside - TradingView
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore - Bez Kabli
Tyra Biosciences (TYRA) Slips Slightly as Stock Holds Between Key Support and Resistance LevelsPro Level Trade Signals - Newser
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY - PR Newswire
Tyra Biosciences (TYRA) Q1 2026 Miss: What Went WrongCommunity Buy Signals - Newser
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials - Sahm
Tyra Biosciences (TYRA) Q1 2026 Disappoints — EPS $-0.64 Below $-0.60 ViewsAnalyst Consensus Shift - Newser
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform - GuruFocus
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com - Investing.com Canada
Tyra Biosciences Soars 280% in a Year as HighVista Strategies Boosts StakeSenior Analyst Forecasts - Newser
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares - Yahoo Finance
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile? - Sahm
(TYRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Commodore Capital (TYRA) reports 2.48M-share, 4.2% stake (Mar 31, 2026) - Stock Titan
Janus Henderson (TYRA) discloses 3.89M shares; 7.2% stake (Schedule 13G/A) - Stock Titan
Canaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Todd Harris reports 2.91M shares in Tyra Biosciences (TYRA) - Stock Titan
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum - Yahoo! Finance Canada
Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC - Traders Union
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $45 to $59 - Moomoo
TYRA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
TYRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Tyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results - MarketBeat
Hot Picks: Cancer biotech stocks gain ground amid M&A activity - BNN Bloomberg
TYRA: Pivotal data for an oral FGFR3 inhibitor could transform care in NMIBC, UTUC, and achondroplasia - TradingView
Tyra Biosciences Q1 Net Loss Widens - Moomoo
Tyra Biosciences, Inc. Q1 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Tyra Biosciences Advances Dabogratinib FGFR3 Clinical Trials, Reports Q1 2026 Financial Results and Milestones - Minichart
Tyra Biosciences: Cash, Cash Equivalents and Marketable Securities of $383.5M at 1Q; Runway Into 2H 2028 >TYRA - Moomoo
Tyra Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (TYRA) Tyra Biosciences Posts Q1 Net Loss $0.64 a Share, vs. FactSet Est of $0.59 Loss - marketscreener.com
Tyra Biosciences 1Q 2026: Net income $(39.3M), EPS $(0.64) — 10-Q Summary - TradingView
Tyra Biosciences (NASDAQ: TYRA) widens Q1 loss but extends cash runway - Stock Titan
Tyra Biosciences reports Q1 2026 net loss $39.3M, cash $383.5M; advances dabogratinib programs - TradingView
[8-K] Tyra Biosciences, Inc. Reports Material Event - Stock Titan
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - PR Newswire
TYRA (Nasdaq) affiliate sells 8,000 shares on three dates totaling reported proceeds - Stock Titan
Farallon funds disclose multi‑percent TYRA holdings (TYRA) - Stock Titan
TradingKey - TradingKey
Why Tyra Biosciences (TYRA) earnings beat or miss matters less than you think - Newser
Tyra Biosciences earnings on deck as bladder cancer data looms By Investing.com - Investing.com South Africa
Tyra Biosciences earnings on deck as bladder cancer data looms - Investing.com UK
Tyra Biosciences Q4 Loss Widens - Moomoo
Three Tyra Biosciences investor events start May 13, with webcasts - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) CMO awarded RSUs and 85,000-share option - Stock Titan
Tyra Biosciences (TYRA) awards CFO Alan Fuhrman RSUs and 67,000 options - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) CEO receives new RSU and 265,000-share option awards - Stock Titan
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):